Shares of Clorox Co. CLX sank 0.06% to $157.47 Monday, on what proved to be an all-around favorable trading session for the ...

What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

After hours: January 16 at 5:30:23 PM EST ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

With no approved vaccines to date, C. diff causes nearly 30,000 deaths each year in the US, and recurrent infections with the bacterium make up 10%-15% of all hospital-treated infections.

After hours: January 16 at 5:30:23 p.m. EST ...

Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

Tinidazole is a structural analog of metronidazole and has been available in Europe for more than 2 decades. After activation, its toxic intermediates covalently bind to DNA, resulting in DNA ...

An international study of cancer patients with Clostridioides difficile infection (CDI ... would safely reduce antibiotic duration compared with usual care, in which C-reactive protein is used to ...

What-the-Diff gives you a summary on all changes and speeds up your review process significantly. What The Diff analyzes the changes of your pull requests and gives you and your team a summary of all ...